BioMark Diagnostics (TSE:BUX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioMark Diagnostics has made a significant advancement in breast cancer diagnosis with its liquid biopsy platform capable of predicting estrogen receptor status with 93% accuracy. This breakthrough promises to revolutionize breast cancer diagnosis and treatment, potentially saving lives through earlier diagnoses and personalized treatment options.
For further insights into TSE:BUX stock, check out TipRanks’ Stock Analysis page.